statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gagnants
L'action Kineta (NASDAQ:KA) a mont lundi de 16,77% 0,63 dollars lors de la session after-market.
Le titre Windtree Therapeutics (NASDAQ:WINT) a mont de 14,63% 0,47 dollars.
Le titre...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 08/04/2024

Titoli in rialzo
Le azioni di Kineta (NASDAQ:KA) hanno guadagnato l'11,21% a 0,60 dollari durante la sessione after-market di luned .
Le azioni di Finch Therapeutics Gr (NASDAQ:FNCH) sono salite...

12 titoli sanitari in movimento, after-market del 08/04/2024

Gagnants
L'action Kineta (NASDAQ:KA) a grimp mercredi de 8,46% 0,58 dollars lors de la session after-market.
Le titre Simulations Plus (NASDAQ:SLP) a mont de 8,07% 41,50 dollars. La soci t a...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 03/04/2024

Kineta, Inc. (NASDAQ:KA  Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 75,300 shares, a...

Kineta, Inc. (NASDAQ:KA) Short Interest Update

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
KA stock results show that Kineta beat analyst estimates for earnings per share the fourth quarter of 2023.
The post KA Stock Earnings...

KA Stock Earnings: Kineta Beats EPS for Q4 2023

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose...

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of...

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Get caught up on the latest technology and startup news from the past week. Here are the most popular stories on GeekWire for the week of Feb. 25, 2024.
Sign up to receive these updates every Sunday...

Week in Review: Most popular stories on GeekWire for the week of Feb. 25, 2024

Kineta announced Thursday that it is laying off 64% of its workforce, or seven employees including its CEO Shawn Iadonato as it undergoes a restructuring process.

In a press release, the...

Seattle biotech company Kineta lays off majority of staff, including its CEO

SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...

Kineta Announces Restructuring and Exploration of Strategic Alternatives

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Mercer Island, WA.

Watchers	12,632
52-Wk Low	$0.3339
52-Wk High	$5.39

Volume	132,071.00
52-Wk High	$5.39
52-Wk Low	$0.3339

KA Kineta Inc

About

Feed

News

Sentiment

Fundamentals